Wednesday, 6 October 2010

Novartis MS program guides patients to new oral drug, covers out-of-pocket costs

From the MSRC:

Novartis AG will pay out-of-pocket costs for non-Medicare patients who use the company’s multiple sclerosis pill Gilenya when the drug, to be priced at $4,000 a month, goes on sale in the U.S. this week.  Read full article here.